Annovis Bio (ANVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, will be held virtually, allowing stockholders to attend, vote, and submit questions online.
Proxy materials and annual report are available online, with options to request paper or email copies at no charge.
Registration is required by June 16, 2026, to participate in the virtual meeting.
Voting matters and shareholder proposals
Election of five directors: Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of an amendment to the 2019 Equity Incentive Plan.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and proposals 2, 3, and 4, and "2-YEARS" for the frequency of say-on-pay votes.
Latest events from Annovis Bio
- Annual meeting to vote on directors, auditor, equity plan, executive pay, and ESG priorities.ANVS
Proxy filing30 Apr 2026 - Buntanetap delivers cognitive and motor benefits in AD and PD, with strong safety and market potential.ANVS
Corporate presentation13 Apr 2026 - Buntanetap demonstrates cognitive and motor benefits in late-stage trials for AD and PD.ANVS
Corporate presentation26 Mar 2026 - Pivotal Phase 3 AD trial launched, OLE PD study underway, and cash runway extends into Q3 2026.ANVS
Q4 202516 Mar 2026 - Novel Alzheimer's drug shows strong cognitive gains and disease-modifying potential in trials.ANVS
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - Shareholders will vote virtually on director elections and auditor ratification, with ESG and governance emphasized.ANVS
Proxy Filing2 Dec 2025 - Vote on five director nominees and auditor ratification at the June 17, 2025, virtual meeting.ANVS
Proxy Filing2 Dec 2025 - Phase 3 Alzheimer's trial advances with strong enrollment and improved Q3 financials.ANVS
Q3 202513 Nov 2025 - Phase III Alzheimer's trial advances with strong early results; Parkinson's studies await funding.ANVS
Status Update12 Nov 2025